Merck shares have climbed more than 32% over the past three months, driven largely by broader market recovery and rotation into large-cap pharma names. However, analysts have trimmed their 2026 EPS estimates by an average of 4.5% since October, reflecting concerns around Keytruda’s looming loss of exclusivity in 2028 and projected mid-single-digit declines for its HPV vaccine franchise. With patent expirations on three major oncology and prophylactic products representing roughly 45% of Merck’s current revenues, the near-term stock surge does little to change a bearish consensus that anticipates high-single-digit top-line contraction through 2027.

At the company’s January 12th investor day, management reaffirmed its target of $70 billion in annual sales from next-generation therapies by the mid-2030s, highlighting three late-stage cardiometabolic candidates and a respiratory biologic entering Phase III this year. While these programs could offset some revenue headwinds, peak sales projections for each individual asset range from $4 billion to $6 billion—insufficient to replace the combined $22 billion in annual revenues at risk from Keytruda, Gardasil and two older oncology products. Given regulatory review timelines stretching into 2028–2029 and the probability of pricing pressure in chronic disease categories, investors remain wary that pipeline advances will not fully mitigate the revenue cliff.

Despite the share price recovery, Merck trades at a forward P/E multiple near 17x, a premium to the 13–15x range warranted by its projected 2026–2027 EPS trajectory. Consensus forecasts call for mid- to high-single-digit organic revenue declines in each of the next two fiscal years, and free cash flow is expected to contract by roughly 8% in 2026 as R&D spend ramps up on late-stage candidates. With sell-side ratings clustered around a hold or sell recommendation and less than 20% of analysts maintaining a buy stance, the risk/reward profile remains skewed toward further downside should pipeline setbacks or competitive biosimilar launches materialize.

Merck has increased its dividend for 12 consecutive years, currently yielding around 2.8%. However, the projected payout ratio is set to rise toward 60% by 2027 as earnings soften, compared with a historic average near 50%. Management has signaled commitment to returning at least 50% of free cash flow to shareholders via dividends and buybacks, but balance sheet flexibility may be tested if pipeline investments exceed expectations or a major licensing deal is required to shore up long-term growth. Income-focused investors will be monitoring whether Merck can sustain its dividend growth path without compromising strategic priorities.